NCT06348173View on ClinicalTrials.gov

Response and Remission to Treatment With Anti-IL5/IL5R Antagonists

CompletedOBSERVATIONAL

Enrollment

109

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Asthma

Interventions

DRUG

Mepolizumab

Compare the response to mepolizumab and benralizumab before and after treatment

Trial Locations (1)

H4J 1C5

Hôpital du Sacré-Coeur de Montréal, Montreal

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Université de Montréal

OTHER

NCT06348173 - Response and Remission to Treatment With Anti-IL5/IL5R Antagonists | Biotech Hunter | Biotech Hunter